PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Clinical trials for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for women with platinum-resistant ovarian cancer: drug combo shows promise
Disease control Not yet recruitingThis study tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) in 30 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. …
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for tough ovarian cancer? early trial launches
Disease control Not yet recruitingThis early study tests a new drug called WSK-IM02 in 36 women with ovarian cancer that no longer responds to platinum chemotherapy. The main goal is to check safety and find the best dose. Researchers will also watch for any signs that the drug shrinks tumors.
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC